New vaccine aims to stop deadly infant diarrhea
NCT ID NCT06663436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new Shigella vaccine in 200 healthy African infants to see if it can prevent severe diarrhea. The vaccine was given in two doses, and researchers measured immune responses and safety. The trial is now complete, and results will show whether this approach is promising.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Shigella vaccine (altSonflex1-2-3)
- What this could lead to
- If successful, this vaccine could help protect infants in Africa from severe diarrhea caused by Shigella bacteria.
- What could go wrong
- This is a small, early-phase trial. The vaccine may not produce strong enough immunity or could have side effects. Results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.